Biological aspects of angiogenesis in multiple myeloma

International Journal of Hematology

Volumn 94, Issue 6, 2011, Pages 505-518

  Otjacques, Eléonore ^a   Binsfeld, Marilène ^a   Noel, Agnes ^a   Beguin, Yves ^a   Cataldo, Didier ^a   Caers, Jo ^a,b  

^a UNIVERSITY OF LIÈGE   (Belgium)

^b UNIVERSITY OF LIÈGE   (Belgium)

Author keywords

Angiogenesis; Bone marrow microenvironment; Endothelial cell; Hypoxia; Multiple myeloma

Indexed keywords

ADAM PROTEIN; BORTEZOMIB; CYTOKINE; FIBROBLAST GROWTH FACTOR 2; GELATINASE A; GELATINASE B; HYPOXIA INDUCIBLE FACTOR 1; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 8; LENALIDOMIDE; SCATTER FACTOR; THALIDOMIDE; VASCULOTROPIN A; VASCULOTROPIN C; VASCULOTROPIN D;

ANGIOGENESIS; CELL INTERACTION; ENDOTHELIAL PROGENITOR CELL; ENDOTHELIUM CELL; ENZYME ACTIVATION; EXTRACELLULAR MATRIX; HUMAN; MULTIPLE MYELOMA; NEOVASCULARIZATION (PATHOLOGY); NONHUMAN; PATHOPHYSIOLOGY; REVIEW; STROMA;

ANTINEOPLASTIC AGENTS; CYTOKINES; ENDOTHELIAL CELLS; HUMANS; MULTIPLE MYELOMA; NEOVASCULARIZATION, PATHOLOGIC; STROMAL CELLS;

EID: 84355162753     PISSN: 09255710     EISSN: 18653774     Source Type: Journal    
DOI: 10.1007/s12185-011-0963-z     Document Type: Review

References (117)

1. F Bray, et al. 2002 Estimates of cancer incidence and mortality in Europe in 1995 Eur J Cancer 38 1 99 166 11750846 1:STN:280:DC%2BD38%2Fgt1yitw%3D%3D (Pubitemid 34031832)
2. RA Kyle SV Rajkumar 2006 Monoclonal gammopathy of undetermined significance Br J Haematol 134 6 573 589 16938117 1:CAS:528:DC%2BD28XhtFSgsLbJ (Pubitemid 44255500)
3. J Caers, et al. 2008 Unraveling the biology of multiple myeloma disease: cancer stem cells, acquired intracellular changes and interactions with the surrounding micro-environment Bull Cancer 95 3 301 313 18390410 1:CAS:528:DC%2BD1cXltlahtLs%3D (Pubitemid 351528767)
4. M Mattioli, et al. 2005 Gene expression profiling of plasma cell dyscrasias reveals molecular patterns associated with distinct IGH translocations in multiple myeloma Oncogene 24 15 2461 2473 15735737 1:CAS:528:DC%2BD2MXivFOhurw%3D (Pubitemid 40593037)
5. RA Kyle, et al. 2002 A long-term study of prognosis in monoclonal gammopathy of undetermined significance N Engl J Med 346 8 564 569 11856795 (Pubitemid 34438817)
6. P Carmeliet RK Jain 2000 Angiogenesis in cancer and other diseases Nature 407 6801 249 257 11001068 1:CAS:528:DC%2BD3cXmvVSls74%3D
7. C Jakob, et al. 2006 Angiogenesis in multiple myeloma Eur J Cancer 42 11 1581 1590 16797965 1:CAS:528:DC%2BD28Xns1Grt7k%3D (Pubitemid 44118769)
8. SV Rajkumar, et al. 1999 Bone marrow angiogenesis in patients achieving complete response after stem cell transplantation for multiple myeloma Leukemia 13 3 469 472 10086738 1:STN:280:DyaK1M7osVGnsA%3D%3D (Pubitemid 29108086)
9. A Vacca, et al. 1994 Bone marrow angiogenesis and progression in multiple myeloma Br J Haematol 87 3 503 508 7527645 1:STN:280:DyaK2M%2FosF2ntg%3D%3D (Pubitemid 24230014)
10. M Laroche, et al. 2001 Increased vascularization in myeloma Eur J Haematol 66 2 89 93 11168515 1:STN:280:DC%2BD3M7ltFGluw%3D%3D (Pubitemid 32154101)
11. K Asosingh, et al. 2004 Angiogenic switch during 5T2MM murine myeloma tumorigenesis: role of CD45 heterogeneity Blood 103 8 3131 3137 15070695 1:CAS:528:DC%2BD2cXjsVagsLw%3D (Pubitemid 38451691)
12. AR Perez-Atayde, et al. 1997 Spectrum of tumor angiogenesis in the bone marrow of children with acute lymphoblastic leukemia Am J Pathol 150 3 815 821 9060819 1:STN:280:DyaK2s3hsVCguw%3D%3D (Pubitemid 27106153)
13. O Sezer, et al. 2000 Bone marrow microvessel density is a prognostic factor for survival in patients with multiple myeloma Ann Hematol 79 10 574 577 11100749 1:STN:280:DC%2BD3M%2FltVSrtA%3D%3D
14. SV Rajkumar, et al. 2000 Prognostic value of bone marrow angiogenesis in multiple myeloma Clin Cancer Res 6 8 3111 3116 10955791 1:STN:280: DC%2BD3M%2FmtVWhuw%3D%3D (Pubitemid 30637735)
15. SV Rajkumar, et al. 2002 Bone marrow angiogenesis in 400 patients with monoclonal gammopathy of undetermined significance, multiple myeloma, and primary amyloidosis Clin Cancer Res 8 7 2210 2216 12114422 (Pubitemid 34753592)
16. MG Alexandrakis, et al. 2004 The relation between bone marrow angiogenesis and the proliferation index Ki-67 in multiple myeloma J Clin Pathol 57 8 856 860 15280408 1:CAS:528:DC%2BD2cXnsVagtLg%3D (Pubitemid 39061436)
17. V Baeriswyl G Christofori 2009 The angiogenic switch in carcinogenesis Semin Cancer Biol 19 5 329 337 19482086 1:CAS:528:DC%2BD1MXhsV2msbnL
18. S Kumar, et al. 2004 Bone marrow angiogenic ability and expression of angiogenic cytokines in myeloma: evidence favoring loss of marrow angiogenesis inhibitory activity with disease progression Blood 104 4 1159 1165 15130943 1:CAS:528:DC%2BD2cXmslKgsbw%3D (Pubitemid 39038038)
19. D Hanahan RA Weinberg 2011 Hallmarks of cancer: the next generation Cell 144 5 646 674 21376230 1:CAS:528:DC%2BC3MXjsFeqtrk%3D
20. L Pour, et al. 2010 Levels of angiogenic factors in patients with multiple myeloma correlate with treatment response Ann Hematol 89 4 385 389 19784651 1:CAS:528:DC%2BC3cXit1Ogur4%3D
21. R Fujii S Yaccoby J Epstein 2002 Control of myeloma growth with the anti-angiogenic agent endostatin Blood 96 360a
22. H Urbanska-Rys T Robak 2003 High serum level of endostatin in multiple myeloma at diagnosis but not in the plateau phase after treatment Mediators Inflamm 12 4 229 235 14514474 1:CAS:528:DC%2BD3sXnsVKrtLY%3D (Pubitemid 37297192)
23. H De Raeve, et al. 2004 Angiogenesis and the role of bone marrow endothelial cells in haematological malignancies Histol Histopathol 19 3 935 950 15168356 (Pubitemid 38855074)
24. D Ribatti 2007 The discovery of endothelial progenitor cells. An historical review Leuk Res 31 4 439 444 17113640 1:CAS:528:DC%2BD2sXhs1SksLw%3D (Pubitemid 46198947)
25. A Vacca, et al. 2003 Endothelial cells in the bone marrow of patients with multiple myeloma Blood 102 9 3340 3348 12855563 1:CAS:528: DC%2BD3sXoslersrc%3D (Pubitemid 37314776)
26. T Asahara, et al. 1997 Isolation of putative progenitor endothelial cells for angiogenesis Science 275 5302 964 967 9020076 1:CAS:528:DyaK2sXht1Clu7k%3D (Pubitemid 27087709)
27. S Rafii 2000 Circulating endothelial precursors: mystery, reality, and promise J Clin Invest 105 1 17 19 10619857 1:CAS:528:DC%2BD3cXislSkug%3D%3D (Pubitemid 30036383)
28. T Suda N Takakura Y Oike 2000 Hematopoiesis and angiogenesis Int J Hematol 71 2 99 107 10745620 1:STN:280:DC%2BD3c3gvFOjtQ%3D%3D
29. D Lyden, et al. 2001 Impaired recruitment of bone-marrow-derived endothelial and hematopoietic precursor cells blocks tumor angiogenesis and growth Nat Med 7 11 1194 1201 11689883 1:CAS:528:DC%2BD3MXotlKltLY%3D (Pubitemid 33063774)
30. AH Yin, et al. 1997 AC133, a novel marker for human hematopoietic stem and progenitor cells Blood 90 12 5002 5012 9389720 1:CAS:528:DyaK2sXnvFWkt7Y%3D (Pubitemid 28007217)
31. S Miraglia, et al. 1997 A novel five-transmembrane hematopoietic stem cell antigen: isolation, characterization, and molecular cloning Blood 90 12 5013 5021 9389721 1:CAS:528:DyaK2sXnvFWkt7c%3D (Pubitemid 28007218)
32. H Zhang, et al. 2005 Circulating endothelial progenitor cells in multiple myeloma: implications and significance Blood 105 8 3286 3294 15618473 1:CAS:528:DC%2BD2MXjtlSlsro%3D
33. M Dominici, et al. 2001 Angiogenesis in multiple myeloma: correlation between in vitro endothelial colonies growth (CFU-En) and clinical-biological features Leukemia 15 1 171 176 11243386 1:STN:280:DC%2BD3M7nsl2gsA%3D%3D (Pubitemid 32124082)
34. X Wang Z Zhang C Yao 2011 Angiogenic activity of mesenchymal stem cells in multiple myeloma Cancer Invest 29 1 37 41 21166497
35. C Scavelli, et al. 2008 Vasculogenic mimicry by bone marrow macrophages in patients with multiple myeloma Oncogene 27 5 663 674 17667938 1:CAS:528:DC%2BD1cXhtVKqs7s%3D (Pubitemid 351158901)
36. J Caers, et al. 2007 Neighboring adipocytes participate in the bone marrow microenvironment of multiple myeloma cells Leukemia 21 7 1580 1584 17377589 1:STN:280:DC%2BD2szmtlWrsw%3D%3D (Pubitemid 46965308)
37. B Dankbar, et al. 2000 Vascular endothelial growth factor and interleukin-6 in paracrine tumor-stromal cell interactions in multiple myeloma Blood 95 8 2630 2636 10753844 1:CAS:528:DC%2BD3cXisVait78%3D (Pubitemid 30210543)
38. S Barille, et al. 1997 Metalloproteinases in multiple myeloma: production of matrix metalloproteinase-9 (MMP-9), activation of proMMP-2, and induction of MMP-1 by myeloma cells Blood 90 4 1649 1655 9269785 1:CAS:528: DyaK2sXltlOqsLw%3D (Pubitemid 27355439)
39. M Urashima, et al. 1997 The development of a model for the homing of multiple myeloma cells to human bone marrow Blood 90 2 754 765 9226176 1:CAS:528:DyaK2sXksF2jt7o%3D (Pubitemid 27299116)
40. M Borset, et al. 1996 Hepatocyte growth factor and its receptor c-met in multiple myeloma Blood 88 10 3998 4004 8916966 1:STN:280:DyaK2s%2FnsVGguw%3D%3D (Pubitemid 26383124)
41. D Hose, et al. 2009 Induction of angiogenesis by normal and malignant plasma cells Blood 114 1 128 143 19299335 1:CAS:528:DC%2BD1MXhtVOkurvN
42. AM Byrne DJ Bouchier-Hayes JH Harmey 2005 Angiogenic and cell survival functions of vascular endothelial growth factor (VEGF) J Cell Mol Med 9 4 777 794 16364190 1:CAS:528:DC%2BD2sXlvFKhtLg%3D (Pubitemid 43116546)
43. A Vacca, et al. 2003 A paracrine loop in the vascular endothelial growth factor pathway triggers tumor angiogenesis and growth in multiple myeloma Haematologica 88 2 176 185 12604407 1:CAS:528:DC%2BD3sXotlGhurs%3D (Pubitemid 37101495)
44. K Podar, et al. 2001 Vascular endothelial growth factor triggers signaling cascades mediating multiple myeloma cell growth and migration Blood 98 2 428 435 11435313 1:CAS:528:DC%2BD3MXlt1KrtLw%3D
45. H Uchiyama, et al. 1993 Adhesion of human myeloma-derived cell lines to bone marrow stromal cells stimulates interleukin-6 secretion Blood 82 12 3712 3720 8260708 1:CAS:528:DyaK2cXlt1GhsQ%3D%3D (Pubitemid 24006055)
46. D Chauhan, et al. 1996 Multiple myeloma cell adhesion-induced interleukin-6 expression in bone marrow stromal cells involves activation of NF-kappa B Blood 87 3 1104 1112 8562936 1:CAS:528:DyaK28XnsFGmsQ%3D%3D (Pubitemid 26043538)
47. I Kim, et al. 1994 Cell surface expression and functional significance of adhesion molecules on human myeloma-derived cell lines Br J Haematol 87 3 483 493 7993788 1:CAS:528:DyaK2cXmtVajt7s%3D (Pubitemid 24230012)
48. D Ribatti B Nico A Vacca 2006 Importance of the bone marrow microenvironment in inducing the angiogenic response in multiple myeloma Oncogene 25 31 4257 4266 16518413 1:CAS:528:DC%2BD28XntVWksrY%3D (Pubitemid 44100496)
49. C Birchmeier, et al. 2003 Met, metastasis, motility and more Nat Rev Mol Cell Biol 4 12 915 925 14685170 1:CAS:528:DC%2BD3sXpvFeju7s%3D (Pubitemid 37493640)
50. G Maulik, et al. 2002 Role of the hepatocyte growth factor receptor, c-Met, in oncogenesis and potential for therapeutic inhibition Cytokine Growth Factor Rev 13 1 41 59 11750879 1:CAS:528:DC%2BD3MXpt1ahuro%3D (Pubitemid 34436961)
51. D Hose, et al. 2009 Inhibition of aurora kinases for tailored risk-adapted treatment of multiple myeloma Blood 113 18 4331 4340 19171872 1:CAS:528:DC%2BD1MXlvVGisbY%3D
52. C Seidel, et al. 1998 Elevated serum concentrations of hepatocyte growth factor in patients with multiple myeloma. The Nordic Myeloma Study Group Blood 91 3 806 812 9446640 1:STN:280:DyaK1c7hvVWqtg%3D%3D (Pubitemid 28078282)
53. PW Derksen, et al. 2003 The hepatocyte growth factor/Met pathway controls proliferation and apoptosis in multiple myeloma Leukemia 17 4 764 774 12682635 1:CAS:528:DC%2BD3sXis12isb0%3D (Pubitemid 36519374)
54. NF Andersen, et al. 2005 Syndecan-1 and angiogenic cytokines in multiple myeloma: correlation with bone marrow angiogenesis and survival Br J Haematol 128 2 210 217 15638855 1:CAS:528:DC%2BD2MXhs1Grsr0%3D
55. MG Alexandrakis, et al. 2003 Elevated serum concentration of hepatocyte growth factor in patients with multiple myeloma: correlation with markers of disease activity Am J Hematol 72 4 229 233 12666132 1:CAS:528: DC%2BD3sXjtVChu7k%3D (Pubitemid 36383972)
56. C Basilico D Moscatelli 1992 The FGF family of growth factors and oncogenes Adv Cancer Res 59 115 165 1381547 1:CAS:528:DyaK3sXntlOhuw%3D%3D
57. P Mignatti DB Rifkin 1993 Biology and biochemistry of proteinases in tumor invasion Physiol Rev 73 1 161 195 8419965 1:CAS:528:DyaK3sXitlWhsLs%3D (Pubitemid 23065437)
58. D Ribatti, et al. 1999 In vivo angiogenic activity of urokinase: role of endogenous fibroblast growth factor-2 J Cell Sci 112 Pt 23 4213 4221 10564640 1:CAS:528:DC%2BD3cXktFKgsw%3D%3D (Pubitemid 30122014)
59. A Vacca, et al. 1999 Bone marrow neovascularization, plasma cell angiogenic potential, and matrix metalloproteinase-2 secretion parallel progression of human multiple myeloma Blood 93 9 3064 3073 10216103 1:CAS:528:DyaK1MXivVyltbs%3D (Pubitemid 29200799)
60. G Bisping, et al. 2003 Paracrine interactions of basic fibroblast growth factor and interleukin-6 in multiple myeloma Blood 101 7 2775 2783 12517814 1:CAS:528:DC%2BD3sXivVWns7o%3D (Pubitemid 36857643)
61. A Noel M Jost E Maquoi 2008 Matrix metalloproteinases at cancer tumor-host interface Semin Cell Dev Biol 19 1 52 60 17625931 1:CAS:528:DC%2BD2sXhsVeqtLbN (Pubitemid 350235981)
62. R Kalluri 2003 Basement membranes: structure, assembly and role in tumour angiogenesis Nat Rev Cancer 3 6 422 433 12778132 1:CAS:528:DC%2BD3sXktFOnsbw%3D (Pubitemid 37328846)
63. P Nyberg L Xie R Kalluri 2005 Endogenous inhibitors of angiogenesis Cancer Res 65 10 3967 3979 15899784 1:CAS:528:DC%2BD2MXktlSms7Y%3D (Pubitemid 40775631)
64. Monteiro Torres PH, Limaverde Soares Costa Sousa G, Pascutti PG. Structural analysis of the N-terminal fragment of the antiangiogenic protein endostatin: a molecular dynamics study. Proteins. 2011;79(9):2684-92.
65. E Van Valckenborgh, et al. 2002 Upregulation of matrix metalloproteinase-9 in murine 5T33 multiple myeloma cells by interaction with bone marrow endothelial cells Int J Cancer 101 6 512 518 12237890
66. K Vanderkerken, et al. 2003 Multiple myeloma biology: lessons from the 5TMM models Immunol Rev 194 196 206 12846816 1:CAS:528:DC%2BD3sXmsV2ms7Y%3D (Pubitemid 36896125)
67. MG Alexandrakis, et al. 2007 Relationship between serum levels of vascular endothelial growth factor, hepatocyte growth factor and matrix metalloproteinase-9 with biochemical markers of bone disease in multiple myeloma Clin Chim Acta 379 1-2 31 35 17234170 1:CAS:528:DC%2BD2sXislKit7Y%3D (Pubitemid 46366964)
68. N Rocks, et al. 2008 Emerging roles of ADAM and ADAMTS metalloproteinases in cancer Biochimie 90 2 369 379 17920749 1:CAS:528:DC%2BD1cXhsVGktb0%3D (Pubitemid 351172571)
69. C Bret, et al. 2011 Gene expression profile of ADAMs and ADAMTSs metalloproteinases in normal and malignant plasma cells and in the bone marrow environment Exp Hematol. 39 546 557 21316416 1:CAS:528:DC%2BC3MXlsFKisrY%3D
70. A Karadag M Zhou PI Croucher 2006 ADAM-9 (MDC-9/meltrin-gamma), a member of the a disintegrin and metalloproteinase family, regulates myeloma-cell-induced interleukin-6 production in osteoblasts by direct interaction with the alpha(v)beta5 integrin Blood 107 8 3271 3278 16373656 1:CAS:528:DC%2BD28Xjs1Oks7s%3D
71. T Hideshima, et al. 2001 Novel therapies targeting the myeloma cell and its bone marrow microenvironment Semin Oncol 28 6 607 612 11740818 1:CAS:528:DC%2BD38XjvVSmtA%3D%3D (Pubitemid 33134420)
72. N Giuliani, et al. 2002 Human myeloma cells stimulate the receptor activator of nuclear factor-kappa B ligand (RANKL) in T lymphocytes: a potential role in multiple myeloma bone disease Blood 100 13 4615 4621 12393684 1:CAS:528:DC%2BD38XpsFCqt78%3D (Pubitemid 35429706)
73. SK Martin, et al. 2006 Tumor angiogenesis is associated with plasma levels of stromal-derived factor-1alpha in patients with multiple myeloma Clin Cancer Res 12 23 6973 6977 17145816 1:CAS:528:DC%2BD28Xht1Kns7vF (Pubitemid 44974491)
74. E Terpos, et al. 2005 Significance of macrophage inflammatory protein-1 alpha (MIP-1alpha) in multiple myeloma Leuk Lymphoma 46 12 1699 1707 16263571 1:CAS:528:DC%2BD2MXhtFyrt7%2FI (Pubitemid 43203102)
75. LW Fisher, et al. 1987 Purification and partial characterization of small proteoglycans I and II, bone sialoproteins I and II, and osteonectin from the mineral compartment of developing human bone J Biol Chem 262 20 9702 9708 3597437 1:CAS:528:DyaL2sXkvFaht7Y%3D (Pubitemid 17102617)
76. J Caers, et al. 2006 The involvement of osteopontin and its receptors in multiple myeloma cell survival, migration and invasion in the murine 5T33MM model Br J Haematol 132 4 469 477 16412019 1:CAS:528:DC%2BD28XislCqu7k%3D (Pubitemid 43381618)
77. S Colla, et al. 2005 Human myeloma cells express the bone regulating gene Runx2/Cbfa1 and produce osteopontin that is involved in angiogenesis in multiple myeloma patients Leukemia 19 12 2166 2176 16208410 1:CAS:528: DC%2BD2MXht1ems7fM (Pubitemid 41741611)
78. MC Brahimi-Horn J Pouyssegur 2007 Harnessing the hypoxia-inducible factor in cancer and ischemic disease Biochem Pharmacol 73 3 450 457 17101119 1:CAS:528:DC%2BD2sXht1Slsw%3D%3D (Pubitemid 44958373)
79. RH Wenger 2002 Cellular adaptation to hypoxia: O2-sensing protein hydroxylases, hypoxia-inducible transcription factors, and O2-regulated gene expression FASEB J 16 10 1151 1162 12153983 1:CAS:528:DC%2BD38XlslWrs78%3D (Pubitemid 34815403)
80. EB Rankin AJ Giaccia 2008 The role of hypoxia-inducible factors in tumorigenesis Cell Death Differ 15 4 678 685 18259193 1:CAS:528: DC%2BD1cXjtl2jur8%3D (Pubitemid 351405072)
81. GL Wang, et al. 1995 Hypoxia-inducible factor 1 is a basic helix-loop-helix-PAS heterodimer regulated by cellular O2 tension Proc Natl Acad Sci USA 92 12 5510 5514 7539918 1:CAS:528:DyaK2MXmtFOgs7k%3D
82. YG Yoo, et al. 2009 An essential role of the HIF-1alpha-c-Myc axis in malignant progression Ann NY Acad Sci. 1177 198 204 19845622 1:CAS:528:DC%2BD1MXhsFWksr%2FL
83. W Zundel, et al. 2000 Loss of PTEN facilitates HIF-1-mediated gene expression Genes Dev 14 4 391 396 10691731 1:CAS:528:DC%2BD3cXhsFCgt7w%3D (Pubitemid 30131884)
84. Y Hu, et al. 2009 Inhibition of hypoxia-inducible factor-1 function enhances the sensitivity of multiple myeloma cells to melphalan Mol Cancer Ther 8 8 2329 2338 19671732 1:CAS:528:DC%2BD1MXpvFCmsrg%3D
85. JS Harrison, et al. 2002 Oxygen saturation in the bone marrow of healthy volunteers Blood 99 1 394 11783438 1:CAS:528:DC%2BD38XivF2mug%3D%3D
86. S Colla, et al. 2010 Low bone marrow oxygen tension and hypoxia-inducible factor-1alpha overexpression characterize patients with multiple myeloma: role on the transcriptional and proangiogenic profiles of CD138(+) cells Leukemia 24 11 1967 1970 20811474 1:STN:280:DC%2BC3cblvVOqtw%3D%3D
87. K Asosingh, et al. 2005 Role of the hypoxic bone marrow microenvironment in 5T2MM murine myeloma tumor progression Haematologica 90 6 810 817 15951294 1:CAS:528:DC%2BD2MXnvVWku7k%3D (Pubitemid 40897223)
88. AC Zannettino, et al. 2005 Elevated serum levels of stromal-derived factor-1alpha are associated with increased osteoclast activity and osteolytic bone disease in multiple myeloma patients Cancer Res 65 5 1700 1709 15753365 1:CAS:528:DC%2BD2MXitVOjsLw%3D (Pubitemid 40478595)
89. SK Martin, et al. 2010 Hypoxia-inducible factor-2 is a novel regulator of aberrant CXCL12 expression in multiple myeloma plasma cells Haematologica 95 5 776 784 20015878 1:CAS:528:DC%2BC3cXht1yrsbzN
90. PH Maxwell, et al. 1999 The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis Nature 399 6733 271 275 10353251 1:CAS:528:DyaK1MXjsFyqt74%3D (Pubitemid 29246458)
91. E Hatzimichael, et al. 2009 Von Hippel-Lindau methylation status in patients with multiple myeloma: a potential predictive factor for the development of bone disease Clin Lymphoma Myeloma 9 3 239 242 19525194 1:CAS:528:DC%2BD1MXosVerurY%3D
92. CM Eischen, et al. 1999 Disruption of the ARF-Mdm2-p53 tumor suppressor pathway in Myc-induced lymphomagenesis Genes Dev 13 20 2658 2669 10541552 1:CAS:528:DyaK1MXnt1Wqs74%3D (Pubitemid 29508553)
93. P Modrich R Lahue 1996 Mismatch repair in replication fidelity, genetic recombination, and cancer biology Annu Rev Biochem 65 101 133 8811176 1:CAS:528:DyaK28XktFamt7k%3D (Pubitemid 26250606)
94. A Menssen H Hermeking 2002 Characterization of the c-MYC-regulated transcriptome by SAGE: identification and analysis of c-MYC target genes Proc Natl Acad Sci USA 99 9 6274 6279 11983916 1:CAS:528:DC%2BD38XjslWnsbs%3D (Pubitemid 34493302)
95. J Zhang, et al. 2009 Targeting angiogenesis via a c-Myc/hypoxia-inducible factor-1alpha-dependent pathway in multiple myeloma Cancer Res 69 12 5082 5090 19509231 1:CAS:528:DC%2BD1MXnt1equr4%3D
96. AC Koong, et al. 1994 Hypoxic activation of nuclear factor-kappa B is mediated by a Ras and Raf signaling pathway and does not involve MAP kinase (ERK1 or ERK2) Cancer Res 54 20 5273 5279 7923153 1:CAS:528:DyaK2cXmsFejtrY%3D (Pubitemid 24336013)
97. T Karashima, et al. 2003 Nuclear factor-kappaB mediates angiogenesis and metastasis of human bladder cancer through the regulation of interleukin-8 Clin Cancer Res 9 7 2786 2797 12855659 1:CAS:528:DC%2BD3sXlt1yrsLY%3D (Pubitemid 36842125)
98. CM Annunziata, et al. 2007 Frequent engagement of the classical and alternative NF-kappaB pathways by diverse genetic abnormalities in multiple myeloma Cancer Cell 12 2 115 130 17692804 1:CAS:528:DC%2BD2sXps1art74%3D (Pubitemid 47199123)
99. JJ Keats, et al. 2007 Promiscuous mutations activate the noncanonical NF-kappaB pathway in multiple myeloma Cancer Cell 12 2 131 144 17692805 1:CAS:528:DC%2BD2sXps1art78%3D (Pubitemid 47208626)
100. P van Uden NS Kenneth S Rocha 2008 Regulation of hypoxia-inducible factor-1alpha by NF-kappaB Biochem J 412 3 477 484 18393939
101. YJ Jung, et al. 2003 IL-1beta-mediated up-regulation of HIF-1alpha via an NFkappaB/COX-2 pathway identifies HIF-1 as a critical link between inflammation and oncogenesis FASEB J 17 14 2115 2117 12958148 1:CAS:528:DC%2BD3sXovFOhsb0%3D
102. Q Qiao, et al. 2010 NF-kappaB mediates aberrant activation of HIF-1 in malignant lymphoma Exp Hematol 38 12 1199 1208 20813154 1:CAS:528: DC%2BC3cXhsVGnsLrL
103. SY Nam, et al. 2011 A hypoxia-dependent upregulation of hypoxia-inducible factor-1 by nuclear factor-kappaB promotes gastric tumour growth and angiogenesis Br J Cancer 104 1 166 174 21119667 1:CAS:528:DC%2BC3MXhs1egsA%3D%3D
104. HC Kwon, et al. 2010 Clinicopathological significance of nuclear factor-kappa B, HIF-1 alpha, and vascular endothelial growth factor expression in stage III colorectal cancer Cancer Sci 101 6 1557 1561 20398057 1:CAS:528:DC%2BC3cXns1Sksbs%3D
105. RJ D'Amato, et al. 1994 Thalidomide is an inhibitor of angiogenesis Proc Natl Acad Sci USA 91 9 4082 4085 7513432 (Pubitemid 24139577)
106. A Vacca, et al. 2005 Thalidomide downregulates angiogenic genes in bone marrow endothelial cells of patients with active multiple myeloma J Clin Oncol Off J Am Soc Clin Oncol 23 23 5334 5346 1:CAS:528:DC%2BD2MXpslOrtLg%3D (Pubitemid 46206987)
107. SV Rajkumar, et al. 2005 Combination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed myeloma Blood 106 13 4050 4053 16118317 1:CAS:528:DC%2BD2MXhtlaltrzN (Pubitemid 41775908)
108. PG Richardson, et al. 2006 A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma Blood 108 10 3458 3464 16840727 1:CAS:528:DC%2BD28Xht1ahsLzO
109. S Lentzsch, et al. 2003 Immunomodulatory analogs of thalidomide inhibit growth of Hs Sultan cells and angiogenesis in vivo Leukemia 17 1 41 44 12529658 1:CAS:528:DC%2BD3sXjsFymtQ%3D%3D (Pubitemid 36175886)
110. L Lu, et al. 2009 The anti-cancer drug lenalidomide inhibits angiogenesis and metastasis via multiple inhibitory effects on endothelial cell function in normoxic and hypoxic conditions Microvasc Res 77 2 78 86 18805433 1:CAS:528:DC%2BD1MXisFWnsrc%3D
111. A De Luisi, et al. 2011 Lenalidomide restrains motility and overangiogenic potential of bone marrow endothelial cells in patients with active multiple myeloma Clin Cancer Res 17 7 1935 1946 21307145
112. S Mitra-Kaushik, et al. 2004 Effects of the proteasome inhibitor PS-341 on tumor growth in HTLV-1 Tax transgenic mice and Tax tumor transplants Blood 104 3 802 809 15090453 1:CAS:528:DC%2BD2cXmtlCkur4%3D (Pubitemid 38970577)
113. AM Roccaro, et al. 2006 Bortezomib mediates antiangiogenesis in multiple myeloma via direct and indirect effects on endothelial cells Cancer Res 66 1 184 191 16397231 1:CAS:528:DC%2BD28XhsFWhtw%3D%3D (Pubitemid 43166024)
114. J De Vos, et al. 2002 Comparison of gene expression profiling between malignant and normal plasma cells with oligonucleotide arrays Oncogene 21 44 6848 6857 12360412 (Pubitemid 35221928)
115. NC Munshi, et al. 2004 Identification of genes modulated in multiple myeloma using genetically identical twin samples Blood 103 5 1799 1806 12969976 1:CAS:528:DC%2BD2cXhvVOhsbY%3D (Pubitemid 38268976)
116. H Bao, et al. 2009 Overexpression of Annexin II affects the proliferation, apoptosis, invasion and production of proangiogenic factors in multiple myeloma Int J Hematol 90 2 177 185 19585213 1:CAS:528: DC%2BD1MXhtVeitbvI
117. A Seckinger, et al. 2009 Bone morphogenic protein 6: a member of a novel class of prognostic factors expressed by normal and malignant plasma cells inhibiting proliferation and angiogenesis Oncogene 28 44 3866 3879 19718049 1:CAS:528:DC%2BD1MXhtVKhs7zE